Suppr超能文献

相似文献

1
Inflammatory cell migration into the central nervous system: a few new twists on an old tale.
Brain Pathol. 2007 Apr;17(2):243-50. doi: 10.1111/j.1750-3639.2007.00067.x.
2
The blood-brain barrier, chemokines and multiple sclerosis.
Biochim Biophys Acta. 2011 Feb;1812(2):220-30. doi: 10.1016/j.bbadis.2010.07.019. Epub 2010 Aug 6.
3
Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke.
Biochim Biophys Acta. 2016 Mar;1862(3):461-71. doi: 10.1016/j.bbadis.2015.10.018. Epub 2015 Oct 23.
4
Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details.
Curr Opin Immunol. 2006 Dec;18(6):683-9. doi: 10.1016/j.coi.2006.09.005. Epub 2006 Sep 28.
5
Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system.
Brain Res Bull. 2003 Aug 15;61(3):347-55. doi: 10.1016/s0361-9230(03)00097-2.
7
Molecular targets for disrupting leukocyte trafficking during multiple sclerosis.
Expert Rev Mol Med. 2007 Jul 19;9(20):1-19. doi: 10.1017/S1462399407000397.
9
Model systems for studies of leukocyte migration across the blood - brain barrier.
J Neurovirol. 1999 Dec;5(6):579-90. doi: 10.3109/13550289909021287.
10
Chemokine-based therapies for MS: how do we get there from here?
Trends Immunol. 2001 Nov;22(11):591-3. doi: 10.1016/s1471-4906(01)02056-7.

引用本文的文献

1
Mast cells proliferate in the peri-hippocampal space during early development and modulate local and peripheral immune cells.
Dev Cell. 2025 Mar 24;60(6):853-870.e7. doi: 10.1016/j.devcel.2024.11.015. Epub 2024 Dec 10.
2
Effects of HTLV-1 on leukocyte trafficking and migration in ACs compared to healthy individuals.
BMC Res Notes. 2024 Aug 10;17(1):222. doi: 10.1186/s13104-024-06887-5.
3
Animal models of immune-mediated demyelinating polyneuropathies.
Autoimmunity. 2024 Dec;57(1):2361745. doi: 10.1080/08916934.2024.2361745. Epub 2024 Jun 8.
4
Role of inflammatory cytokine burst in neuro-invasion of Japanese Encephalitis virus infection: an immunotherapeutic approaches.
J Neurovirol. 2024 Jun;30(3):251-265. doi: 10.1007/s13365-024-01212-z. Epub 2024 Jun 6.
5
CNS Viral Infections-What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches.
CNS Drugs. 2024 May;38(5):349-373. doi: 10.1007/s40263-024-01082-3. Epub 2024 Apr 5.
6
Extracellular vesicles incorporating retrovirus-like capsids for the enhanced packaging and systemic delivery of mRNA into neurons.
Nat Biomed Eng. 2024 Apr;8(4):415-426. doi: 10.1038/s41551-023-01150-x. Epub 2024 Feb 19.
7
Blood-Brain Barrier Models for Neuroinfectious Diseases: A Narrative Review.
Curr Neuropharmacol. 2024;22(8):1344-1373. doi: 10.2174/1570159X22666231207114346.
8
Chronic cerebral hypoperfusion: a critical feature in unravelling the etiology of vascular cognitive impairment.
Acta Neuropathol Commun. 2023 Jun 12;11(1):93. doi: 10.1186/s40478-023-01590-1.

本文引用的文献

1
What is the blood-brain barrier (not)?
Trends Immunol. 2007 Jan;28(1):5-11. doi: 10.1016/j.it.2006.11.007. Epub 2006 Nov 30.
2
Blockade of chemokine signaling in patients with multiple sclerosis.
Neurology. 2006 Nov 28;67(10):1880-3. doi: 10.1212/01.wnl.0000244420.68037.86.
3
What is immune privilege (not)?
Trends Immunol. 2007 Jan;28(1):12-8. doi: 10.1016/j.it.2006.11.004. Epub 2006 Nov 28.
7
Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details.
Curr Opin Immunol. 2006 Dec;18(6):683-9. doi: 10.1016/j.coi.2006.09.005. Epub 2006 Sep 28.
8
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
N Engl J Med. 2006 Sep 14;355(11):1124-40. doi: 10.1056/NEJMoa052643.
9
Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Curr Opin Neurol. 2006 Aug;19(4):341-9. doi: 10.1097/01.wco.0000236612.66839.a2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验